10:06 AM EST - Ventripoint Diagnostics Ltd : Announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound images into three-dimensional cardiac measurements. The Company is expanding subscription-based access, hospital demonstrations, and customer-engagement programs to help more hospitals evaluate and adopt VMS+. Ventripoint Diagnostics Ltd
shares V.VPT are trading unchanged at $0.10.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=VPT%3ACC&qmodStoryID=4998317363451571
